Literature DB >> 8652869

Hearing loss and congenital symptomatic cytomegalovirus infection: a case report of multidisciplinary longitudinal assessment and intervention.

F P McCollister1, L C Simpson, A J Dahle, R F Pass, K B Fowler, C S Amos, T J Boll.   

Abstract

More than 6000 children born annually in this country have hearing loss resulting from congenital cytomegalovirus (CMV) infection, the leading nonhereditary congenital cause of hearing loss in children. This exemplary congenital symptomatic CMV case focuses on the results of longitudinal audiologic, educational, medical, psychological, and visual evaluations and intervention. Decreased ocular motor control and visual acuity were observed as was bilateral deterioration of hearing from 3 days though 9 years of age. Treatment with dexamethasone and histamine resulted in almost complete reversal of the most recent progression of hearing loss in the left ear.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8652869

Source DB:  PubMed          Journal:  J Am Acad Audiol        ISSN: 1050-0545            Impact factor:   1.664


  3 in total

1.  Hearing loss in perinatally HIV-infected and HIV-exposed but uninfected children and adolescents.

Authors:  Peter Torre; Bret Zeldow; Howard J Hoffman; Ashley Buchanan; George K Siberry; Mabel Rice; Patricia A Sirois; Paige L Williams
Journal:  Pediatr Infect Dis J       Date:  2012-08       Impact factor: 2.129

2.  Rehabilitation and outcome of severe profound deafness in a group of 16 infants affected by congenital cytomegalovirus infection.

Authors:  Andrea Ciorba; Roberto Bovo; Patrizia Trevisi; Chiara Bianchini; Rosa Arboretti; Alessandro Martini
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-03-13       Impact factor: 2.503

3.  Comprehensive molecular-genetic analysis of mid-frequency sensorineural hearing loss.

Authors:  Zuzana Pavlenkova; Lukas Varga; Silvia Borecka; Miloslav Karhanek; Miloslava Huckova; Martina Skopkova; Milan Profant; Daniela Gasperikova
Journal:  Sci Rep       Date:  2021-11-18       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.